712 results on '"Doehner, Hartmut"'
Search Results
2. Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
3. Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial
4. How I treat refractory and relapsed acute myeloid leukemia
5. Acute promyelocytic leukemia: long-term outcomes from the HARMONY project
6. Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut
7. Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study
8. Model-based optimal AML consolidation treatment
9. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09–09): a randomised, open-label, multicentre, phase 3 trial
10. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial
11. Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine
12. Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications
13. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
14. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
15. Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status
16. Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies
17. Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia
18. Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal
19. Neurologic Complications of the Central Nervous System after Allogeneic Stem Cell Transplantation: The Role of Transplantation-Associated Thrombotic Microangiopathy as a Potential Underreported Cause
20. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial
21. Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma
22. Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations
23. Deregulated expression of circular RNAs in acute myeloid leukemia
24. Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways
25. Rearrangements involving 11q23.3/KMT2A in adult AML:mutational landscape and prognostic implications - a HARMONY study
26. Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial
27. Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication
28. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial
29. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations
30. The ParaHox gene Cdx4 induces acute erythroid leukemia in mice
31. Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group
32. IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia
33. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD
34. FBXW7 mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL
35. AML-457 Oral Azacitidine (Oral-AZA) in Patients With Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Long-Term Overall Survival (OS) Results from the Phase 3 QUAZAR AML-001 Trial
36. AML-440 Prognosis of Molecularly-Defined Secondary Acute Myeloid Leukemia Patients
37. AML-432 Overall Survival (OS) by IDH2 Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant-IDH2 Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial
38. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML
39. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
40. Impact of Fluoroquinolone Prophylaxis on Reduced Infection-Related Mortality among Patients with Neutropenia and Hematologic Malignancies
41. Automated Array-Based Genomic Profiling in Chronic Lymphocytic Leukemia: Development of a Clinical Tool and Discovery of Recurrent Genomic Alterations
42. IL-33–ST2 signaling promotes stemness in subtypes of myeloid leukemia cells through the Wnt and Notch pathways
43. Human Chromosome 7: DNA Sequence and Biology
44. Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation: A Comparison of Eculizumab Therapy and Conventional Therapy
45. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study
46. Azacitidine in adult patients with acute myeloid leukemia
47. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
48. Table S1 from Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence
49. Figure S1 - Figure S8 from Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence
50. Data from Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.